<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alopecia areata: Clinical manifestations and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alopecia areata: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Alopecia areata: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew G Messenger, MD, FRCP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Hordinsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 05, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alopecia areata is a chronic, immune-mediated disorder that targets anagen hair follicles and causes nonscarring hair loss. The condition most commonly presents with discrete, smooth patches of alopecia on the scalp but may also occur in other hair-bearing areas, such as the eyebrows, eyelashes, beard, and extremities  (<a class="graphic graphic_picture graphicRef105455 graphicRef120370 graphicRef120368 graphicRef76247 graphicRef52784 graphicRef120371 graphicRef72738 graphicRef66057" href="/d/graphic/105455.html" rel="external">picture 1A-H</a>). In severe alopecia areata, patients may experience loss of all scalp hair (alopecia totalis) or all hair (alopecia universalis)  (<a class="graphic graphic_picture graphicRef50229 graphicRef120375" href="/d/graphic/50229.html" rel="external">picture 2A-B</a>).</p><p>The clinical manifestations and diagnosis of alopecia areata will be discussed here. The treatment of alopecia areata and the general approach to the evaluation and diagnosis of hair loss are reviewed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3319.html" rel="external">"Alopecia areata: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Alopecia areata occurs worldwide. The estimated prevalence is approximately 1 in 1000 people, with a lifetime risk of approximately 2 percent [<a href="#rid1">1,2</a>]. Both children and adults may develop alopecia areata, and the disorder occurs at similar rates in males and females [<a href="#rid1">1</a>]. An analysis of clinical data collected from the population of Olmsted County, Minnesota between 1990 and 2009 revealed a mean age for diagnosis of alopecia areata of 32 years in males and 36 years in females [<a href="#rid3">3</a>].</p><p>Whether there is a seasonal pattern for flares of alopecia areata is unclear. A retrospective study of approximately 450 children with alopecia areata suggested a predilection for disease flares during cold months of the year [<a href="#rid4">4</a>]. Additional study is necessary to confirm this finding.</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Alopecia areata is an autoimmune disease in which hair follicles in the growth phase (anagen) prematurely transition to the nonproliferative involution (catagen) and resting (telogen) phases, leading to sudden hair shedding and inhibition of hair regrowth  (<a class="graphic graphic_figure graphicRef120753" href="/d/graphic/120753.html" rel="external">figure 1</a>). Unlike cicatricial alopecias, the inflammatory process in alopecia areata does not lead to permanent destruction of the hair follicle. (See  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Hair cycle'</a> and  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Cicatricial alopecia'</a>.)</p><p>The mechanisms leading to alopecia areata are not fully understood. Key events may include the loss of follicular immune privilege and the development of an associated T cell-mediated immune attack on cells within the hair bulb. Genetic susceptibility to alopecia areata also plays a role:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loss of immune privilege and immune dysregulation</strong> –<strong> </strong>The combination of loss of immune privilege at the hair follicle and other immunologic events is likely necessary for the development of alopecia areata [<a href="#rid5">5</a>]. The loss of immune privilege is postulated to involve unknown local stressors or events that inhibit the expression of hair follicle immune privilege "guardians" (eg, transforming growth factor [TGF]-beta and alpha-melanocyte-stimulating hormone [MSH]) and stimulate the expression of major histocompatibility complex class I polypeptide-related sequence A (MICA) on hair follicle cells. These events can lead to activation of natural killer cells and local secretion of interferon (IFN)-gamma and interleukin (IL)-15. IFN-gamma stimulates the expression of major histocompatibility complex (MHC)-I protein on hair follicle cells, which may allow the presentation of previously hidden antigens to T cells. IL-15 inhibits suppressive function of regulatory T cells and promotes proliferation of natural killer cells and T cells. </p><p></p><p class="bulletIndent1">IFN-gamma and IL-15 activate target immune cells via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. The importance of this pathway is illustrated by the efficacy of Janus kinase (JAK) inhibitors for alopecia areata [<a href="#rid6">6-8</a>]. (See  <a class="medical medical_review" href="/d/html/3319.html" rel="external">"Alopecia areata: Management", section on 'Other Janus kinase inhibitors'</a>.)</p><p></p><p class="bulletIndent1">A mouse study suggests that a defect in hair follicle immune privilege may not always be necessary, supporting a role for broader immune system dysfunction in the pathogenesis [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic predisposition</strong> – Familial and twin studies support a genetic predisposition to alopecia areata [<a href="#rid10">10-12</a>]. In one study of 206 patients with alopecia areata, 20 percent had a first-degree relative with the disease [<a href="#rid10">10</a>]. In a twin study, among 19 pairs of monozygotic twins, both twins had alopecia areata in 42 percent of twin pairs [<a href="#rid12">12</a>]. In contrast, among 31 pairs of dizygotic twins, both twins had alopecia areata in only 10 percent of twin pairs.</p><p></p><p class="bulletIndent1">Genome-wide association studies have confirmed associations of alopecia areata with human leukocyte antigen (HLA) genes [<a href="#rid13">13-19</a>]. The HLA-DQB1*03 allele, among others, may be an important marker for susceptibility to alopecia areata [<a href="#rid18">18,20</a>].</p><p></p><p class="bulletIndent1">A strong association of alopecia areata with genes within the ULBP gene cluster on chromosome 6q25.1 has also been detected. The ULBP cluster codes for activating ligands of the NKG2D receptor, supporting a role for NK and certain CD8+ T cells in the pathogenesis of this disease [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">Several susceptibility loci that have been associated with other autoimmune diseases (eg, cytotoxic T lymphocyte-associated antigen 4 [CTLA-4], IL-2/IL-21, interleukin-2 receptor-alpha [IL-2RA]) have also been identified, indicating that alopecia areata may share a common pathway with other autoimmune diseases, such as type 1 diabetes mellitus and rheumatoid arthritis. (See  <a class="medical medical_review" href="/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus", section on 'Genetic susceptibility'</a> and  <a class="medical medical_review" href="/d/html/7487.html" rel="external">"HLA and other susceptibility genes in rheumatoid arthritis", section on 'Rheumatoid arthritis susceptibility genes outside the HLA region'</a>.)</p><p></p><p>Other factors, such as infections, drugs, and vaccinations, have been proposed as contributors to episodes of alopecia areata. Some patients report severe stress, especially emotional stress, as a precipitating event, although many patients have no such history. Remote events, such as childhood trauma, have also been associated with the development of alopecia areata in adults [<a href="#rid21">21</a>]. </p><p>A role for vitamin D has been proposed based upon a study that found significantly lower serum levels of 25-hydroxyvitamin D in patients with alopecia areata compared with healthy controls and an inverse correlation between serum vitamin D levels and alopecia areata severity [<a href="#rid22">22</a>]. Additional studies are necessary to determine the relevance of this finding. </p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Key clinical features of alopecia areata include the pattern and speed of hair loss, exclamation point hairs, and associated nail dystrophy.</p><p class="headingAnchor" id="H9"><span class="h2">Hair loss</span><span class="headingEndMark"> — </span>Alopecia areata most commonly occurs on the scalp but may occur on any hair-bearing area, such as the eyelashes, eyebrows, beard, extremities, or other areas  (<a class="graphic graphic_picture graphicRef105455 graphicRef120370 graphicRef120368 graphicRef76247 graphicRef120371 graphicRef72738 graphicRef66057" href="/d/graphic/105455.html" rel="external">picture 1A-D, 1F-H</a>). Patchy alopecia, which manifests as smooth, circular, discrete areas of complete hair loss that develop over a period of a few weeks, is the most common clinical variant. The patches may remain discrete or enlarge and coalesce into bizarre patterns. </p><p>Hair loss is typically asymptomatic. Occasionally, pruritus or a burning sensation precedes the loss of hair. </p><p>In a subset of patients, patchy alopecia progresses to alopecia totalis (total loss of scalp hair) or alopecia universalis (loss of all hair over the entire skin surface). In our experience, alopecia totalis or universalis also occasionally develop rapidly after the onset of diffuse hair loss. (See <a class="local">'Disease course'</a> below.)</p><p>Less common patterns of hair loss include the ophiasis pattern, the rare sisaipho pattern, and the diffuse alopecia areata variants:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ophiasis pattern</strong> – a band-like area of alopecia extending across the occipital scalp  (<a class="graphic graphic_picture graphicRef52784" href="/d/graphic/52784.html" rel="external">picture 1E</a>) [<a href="#rid23">23</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sisaipho (ophiasis inversus) pattern </strong>– alopecia involving the frontal, temporal, and parietal scalp but sparing hair along the scalp periphery  (<a class="graphic graphic_picture graphicRef110290" href="/d/graphic/110290.html" rel="external">picture 3</a>), resembling male pattern hair loss [<a href="#rid24">24</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse alopecia areata</strong> – rapidly progressive, generalized thinning of scalp hair that has also been reported to occur as a rare variant characterized by acute, extensive hair loss that is followed by regrowth of hair within several months (acute diffuse and total alopecia)  (<a class="graphic graphic_picture graphicRef87197" href="/d/graphic/87197.html" rel="external">picture 4</a>) [<a href="#rid25">25,26</a>]</p><p></p><p>In men, involvement of the beard may be the initial or only manifestation  (<a class="graphic graphic_picture graphicRef120371" href="/d/graphic/120371.html" rel="external">picture 1F</a>). In a retrospective study of 55 men with new-onset alopecia areata limited to the beard and a mean follow-up period of 29 months (range 12 to 144 months), 46 percent developed scalp involvement, usually within 12 months [<a href="#rid27">27</a>].</p><p>White hairs initially may be spared in alopecia areata, leading to the appearance of rapid graying of the hair in adults with multiple new lesions.</p><p class="headingAnchor" id="H544255889"><span class="h2">Exclamation point hairs</span><span class="headingEndMark"> — </span>Exclamation point hairs, short broken hairs for which the proximal end of the hair is narrower than the distal end, are a common and pathognomonic finding in alopecia areata  (<a class="graphic graphic_picture graphicRef120367 graphicRef65864" href="/d/graphic/120367.html" rel="external">picture 5A-B</a>) [<a href="#rid1">1</a>]. Exclamation point hairs are typically found at the edges of expanding patches and can be extracted with minimal traction. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Nail abnormalities</span><span class="headingEndMark"> — </span>Nail involvement is estimated to occur in 10 to 20 percent of patients with alopecia areata, with the potential for more frequent nail involvement in patients with severe disease [<a href="#rid1">1</a>]. Nail disease may precede, follow, or coexist with active hair loss. </p><p>Pitting of the nail plate is most common; however, a variety of other disorders, including trachyonychia (roughening of the nail plate), onychorrhexis (longitudinal fissuring of the nail plate), red spotting on the lunulae, onycholysis (separation of the distal nail plate from the nail bed), and onychomadesis (detachment of the proximal nail plate from the nail bed), may also accompany alopecia areata  (<a class="graphic graphic_picture graphicRef73527 graphicRef64919" href="/d/graphic/73527.html" rel="external">picture 6A-B</a>) [<a href="#rid28">28</a>]. Nail involvement has been associated with greater severity of disease [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/13682.html" rel="external">"Overview of nail disorders"</a>.)</p><p class="headingAnchor" id="H953523891"><span class="h1">DISEASE COURSE</span><span class="headingEndMark"> — </span>Spontaneous hair regrowth is common. Around 50 percent of patients with limited patchy hair loss will recover within a year, although almost all will experience more than one episode of the disease [<a href="#rid29">29-31</a>]. Patients may also exhibit persistent areas of alopecia and patches with regrowth of hair simultaneously. Regrowth sometimes begins with the appearance of fine, white vellus hairs  (<a class="graphic graphic_picture graphicRef120373" href="/d/graphic/120373.html" rel="external">picture 7</a>). </p><p>Alternatively, alopecia areata may persist for several years or indefinitely. Approximately 10 percent of patients with patchy disease progress to alopecia totalis or alopecia universalis  (<a class="graphic graphic_picture graphicRef50229 graphicRef120375" href="/d/graphic/50229.html" rel="external">picture 2A-B</a>) [<a href="#rid2">2</a>].</p><p>The following factors have been associated with increased risk for a poor prognosis or high likelihood of relapse [<a href="#rid29">29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Onset in childhood [<a href="#rid32">32,33</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe disease, especially alopecia totalis or alopecia universalis [<a href="#rid32">32</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration of more than one year [<a href="#rid34">34</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Band-like involvement of the peripheral temporal and occipital scalp (ophiasis pattern) [<a href="#rid33">33</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nail disease [<a href="#rid33">33,34</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atopy [<a href="#rid35">35,36</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of alopecia areata [<a href="#rid36">36,37</a>]</p><p></p><p>Long-term outcomes were assessed in a study of 191 patients with alopecia areata who presented to a university dermatology clinic in Italy between 1983 and 1990 and who were contacted by phone in 2005 to give self-reports of their clinical status [<a href="#rid32">32</a>]. Patients with less severe disease at presentation were more likely to report being free of disease at follow-up (68 percent with less than 25 percent hair loss initially, 32 percent with 25 to 50 percent hair loss initially, 8 percent with more than 50 percent hair loss initially). Patients with more severe disease at the time of presentation were also more likely to report worsening patterns of alopecia, such as alopecia totalis and alopecia universalis.</p><p class="headingAnchor" id="H12"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>Alopecia areata has been associated with other dermatologic and nondermatologic disorders.</p><p class="headingAnchor" id="H1935928673"><span class="h2">Dermatologic and systemic disorders</span><span class="headingEndMark"> — </span>One of the largest disease association studies, a nationwide study from Taiwan that included 4334 patients with alopecia areata, found associations with vitiligo (odds ratio [OR] 5.23, 95% CI 3.06-9.00), lupus erythematosus (OR 3.95, 95% CI 3.05-5.11), psoriasis (OR 2.80, 95% CI 2.24-3.50), atopic dermatitis (OR 2.24, 95% CI 1.95-2.58), thyroid disease (OR 1.89, 95% CI 1.68-2.13), and allergic rhinitis (OR 1.29, 95% CI 1.18-1.41) among all patients compared with control subjects and differences in disease associations based upon the age of onset of alopecia areata. Another large study supports an association between alopecia areata and atopic dermatitis. In a case-control study of 2055 patients with alopecia areata and 588 nonalopecic controls, a history of atopic disease was more common in the alopecia group (31 percent) than in controls (21 percent) and was associated with an increased risk of developing alopecia areata (OR 2.00, 95% CI 1.50-2.54) [<a href="#rid38">38</a>].</p><p>An increased risk for type 1 diabetes mellitus has been reported in relatives of individuals with alopecia areata [<a href="#rid39">39</a>]. However, there does not appear to be an increased risk for diabetes among those with the disease.</p><p>Genetic disorders associated with an increased risk for alopecia areata include Down syndrome (trisomy 21, MIM #190685) and polyglandular autoimmune syndrome type 1 (MIM #240300) [<a href="#rid40">40-43</a>]. The latter is a rare autosomal recessive disorder that results from a mutation in the autoimmune regulator (<em>AIRE</em>) gene on chromosome 21. In a study of 1000 institutionalized patients with Down syndrome, the prevalence of alopecia areata was approximately 6 percent [<a href="#rid40">40</a>]. Approximately one-third of patients with polyglandular autoimmune syndrome type 1 have alopecia areata [<a href="#rid43">43,44</a>]. (See  <a class="medical medical_review" href="/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 1 (monogenic)'</a>.)</p><p class="headingAnchor" id="H1777978345"><span class="h2">Psychosocial disorders</span><span class="headingEndMark"> — </span>Hair loss can be distressing for many patients with alopecia areata, leading to reduced quality of life [<a href="#rid45">45,46</a>]. An increased prevalence of anxiety and mood disorders has also been reported in this population [<a href="#rid47">47-49</a>].</p><p class="headingAnchor" id="H1583879577"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The pathologic findings in alopecia areata vary with the acuity of hair loss in the biopsied area [<a href="#rid50">50</a>]. In sites of acute disease with active hair shedding, the presence of intense, peribulbar, lymphocytic, inflammatory infiltrates surrounding anagen follicles is characteristic. These infiltrates are often described as resembling swarms of bees. In addition, signs of follicular insult may be seen, such as follicular edema, cellular necrosis, microvesiculation, and pigment incontinence.</p><p>Follicular miniaturization characterizes the findings in sites of chronic alopecia. The inflammatory infiltrate is variable and usually less pronounced than in early lesions. In addition, because of the transition of anagen follicles to the catagen and telogen stages in alopecia areata, biopsy specimens from areas of chronic involvement reveal high proportions of follicles in catagen or telogen. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The patient history and physical examination are usually sufficient for diagnosis. Clinical features that should raise suspicion for alopecia areata include smooth, discrete areas of rapid hair loss with absent or minimal erythema. (See <a class="local">'Clinical features'</a> above.)</p><p class="headingAnchor" id="H3917576170"><span class="h2">History</span><span class="headingEndMark"> — </span>The patient history should include assessment of the onset and duration of hair loss as well as associated symptoms. In most patients, alopecia areata presents as sudden, asymptomatic hair loss. Given the potential for spontaneous resolution and relapse, patients may report a history of previous hair loss. </p><p>The general approach to the patient interview for hair loss is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Patient interview'</a>.)</p><p class="headingAnchor" id="H381681975"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination should include careful examination of the hair, scalp, and other hair-bearing areas to assess the distribution and extent of hair loss and to detect findings suggestive of other hair or scalp diseases. Smooth, round, or irregular areas of nonscarring hair loss are typical of alopecia areata. (See  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Physical examination'</a>.) </p><p>Close visual inspection may reveal exclamation point hairs, a pathognomonic finding of alopecia areata  (<a class="graphic graphic_picture graphicRef120367" href="/d/graphic/120367.html" rel="external">picture 5A</a>). However, exclamation point hairs are sometimes difficult to detect, and their absence does not exclude the diagnosis. The examination of the scalp should also include assessment for follicular orifices within patches of alopecia, as the absence of these suggests cicatricial (scarring) alopecia. (See  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Visual inspection'</a>.)</p><p>Performance of a hair pull test can be useful for confirming active hair loss. (See  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Hair pull test'</a>.)</p><p>Dermoscopic examination of the hair and scalp (also known as trichoscopy) can be helpful for visualizing findings consistent with alopecia areata [<a href="#rid51">51-54</a>]. Dermoscopic findings include yellow dots, short vellus hairs, black dots, tapering hairs, and broken hairs  (<a class="graphic graphic_table graphicRef115000" href="/d/graphic/115000.html" rel="external">table 1</a> and <a class="graphic graphic_picture graphicRef114978 graphicRef114979 graphicRef114977" href="/d/graphic/114978.html" rel="external">picture 8A-C</a>). Dystrophic hair fibers with monilethrix-like constrictions also may be seen [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/110157.html" rel="external">"Overview of dermoscopy of the hair and scalp"</a>.)</p><p>Examination of the nails may yield nail abnormalities that support the diagnosis. (See <a class="local">'Nail abnormalities'</a> above.)</p><p class="headingAnchor" id="H1489519138"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Biopsies are typically reserved for patients in whom the diagnosis is uncertain despite a careful history and physical examination. Ideally, biopsies are to be taken from the edge of a patch of active hair loss and positioned to include at least a few remaining hairs. </p><p>We typically perform two 4 mm punch biopsies that extend into the subcutaneous fat on the scalp. This allows for routine vertical sectioning of one specimen and horizontal sectioning of the other specimen. If only a single specimen is obtained, horizontal sections will give a better representation of the histopathology. (See <a class="local">'Histopathology'</a> above.)</p><p class="headingAnchor" id="H16"><span class="h1">ADDITIONAL EVALUATION</span><span class="headingEndMark"> — </span>Patients with alopecia areata may benefit from an assessment for thyroid disease and signs or symptoms of other associated disorders. (See <a class="local">'Associated disorders'</a> above.)</p><p class="headingAnchor" id="H3614531920"><span class="h2">Thyroid studies</span><span class="headingEndMark"> — </span>Because of the association between alopecia areata and autoimmune thyroid disease and the relatively high frequency of thyroid disease in the general population, we screen adults and children with alopecia areata for this disorder [<a href="#rid56">56</a>]. Thyroid disorders may be present at the time of diagnosis or develop later in the course of disease. Thus, the subsequent development of symptoms of thyroid disease should prompt re-evaluation. (See <a class="local">'Associated disorders'</a> above and  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function", section on 'Evaluating for thyroid dysfunction'</a>.)</p><p>However, a retrospective study suggests that limiting screening for thyroid dysfunction in children with alopecia areata to certain populations may be reasonable [<a href="#rid57">57</a>]. Among 298 children (ages 10 months to 19 years) with alopecia areata who had thyroid function studies performed, 59 (20 percent) had abnormal results. Factors associated with increased risk for abnormalities included a personal history of Down syndrome or atopy and a family history of thyroid disease. Age, disease duration, pattern of alopecia, and a diagnosis of autoimmune disease were not associated with abnormal thyroid studies. </p><p>Pending additional data to support reduced screening for thyroid disease in children with alopecia areata, we continue to screen all affected children for thyroid disease.</p><p class="headingAnchor" id="H1984881423"><span class="h2">Other</span><span class="headingEndMark"> — </span>Adults and children with clinical signs or symptoms suggestive of other autoimmune diseases should be evaluated for those disorders. In the absence of such features, routine testing for other autoimmune diseases (eg, celiac disease) is not advised [<a href="#rid58">58</a>]. (See <a class="local">'Associated disorders'</a> above.)</p><p class="headingAnchor" id="H17"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of alopecia areata primarily includes other causes of nondiffuse hair loss, such as androgenetic alopecia, cicatricial alopecias, secondary syphilis, tinea capitis, triangular alopecia, and trichotillomania (see  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgenetic alopecia</strong> – Androgenetic alopecia occurs in characteristic male and female patterns and characteristically manifests with slow, progressive hair thinning, rather than the rapid development of areas of complete hair loss that is typical of alopecia areata  (<a class="graphic graphic_picture graphicRef87210 graphicRef83805" href="/d/graphic/87210.html" rel="external">picture 9A-B</a>). The rare sisaipho pattern of alopecia areata can resemble male pattern androgenetic alopecia  (<a class="graphic graphic_picture graphicRef110290" href="/d/graphic/110290.html" rel="external">picture 3</a>). A biopsy can distinguish androgenetic alopecia from alopecia areata in challenging cases. (See  <a class="medical medical_review" href="/d/html/83783.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cicatricial (scarring) alopecia</strong> – Cicatricial alopecia may be the result of diverse pathologies, such as lichen planopilaris, discoid lupus erythematosus  (<a class="graphic graphic_picture graphicRef72588" href="/d/graphic/72588.html" rel="external">picture 10</a>), and folliculitis decalvans. All are characterized by permanent destruction of hair follicles. Hair loss is usually patchy, and there is loss of follicular orifices in sites of alopecia, a finding indicative of scarring. Additional features vary depending on the primary pathology and may include erythema, scaling, follicular plugging, and pustulation. Skin biopsies are often indicated to confirm a diagnosis of cicatricial alopecia. (See  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Cicatricial alopecia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary syphilis</strong> – Areas of patchy hair loss may appear in secondary syphilis. The patches are often described to have a "moth-eaten" appearance rather than the smooth and discrete areas characteristic of alopecia areata  (<a class="graphic graphic_picture graphicRef52213" href="/d/graphic/52213.html" rel="external">picture 11</a>). Serologic testing for syphilis can confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinea capitis</strong> – Tinea capitis typically presents with scaly patches of hair loss on the scalp and is most common in children  (<a class="graphic graphic_picture graphicRef86628 graphicRef86686" href="/d/graphic/86628.html" rel="external">picture 12A-B</a>). Inflammation and cervical lymphadenopathy may also be present. Tinea capitis should always be considered in children presenting with patchy hair loss. In contrast, alopecia areata produces smooth areas of hair loss that lack scale. A potassium hydroxide (KOH) or fungal culture can confirm a diagnosis of tinea capitis. (See  <a class="medical medical_review" href="/d/html/99983.html" rel="external">"Tinea capitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trichotillomania</strong> – Trichotillomania is a disorder in which individuals compulsively pull hair from the scalp or other body areas. The disorder produces unusual patterns of broken hairs of varying length, which leads to a characteristic "wire brush" feel as compared with the smooth hair loss of alopecia areata  (<a class="graphic graphic_picture graphicRef96903 graphicRef96905" href="/d/graphic/96903.html" rel="external">picture 13A-B</a>). The history and physical examination are usually sufficient for diagnosis. However, a biopsy in the area of alopecia can help to differentiate alopecia areata from trichotillomania disorders when necessary. (See  <a class="medical medical_review" href="/d/html/13698.html" rel="external">"Skin picking (excoriation) disorder and related disorders", section on 'Trichotillomania'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triangular alopecia</strong> – Triangular alopecia is a developmental abnormality of hair follicles that presents in infancy or childhood as a triangular or round patch of hair loss near the frontotemporal hair line  (<a class="graphic graphic_picture graphicRef76527" href="/d/graphic/76527.html" rel="external">picture 14</a>). The disorder may be unilateral or bilateral, and persists throughout life. Close examination and biopsy specimens reveal vellus hairs.</p><p></p><p>The diffuse variant of alopecia areata may be difficult to distinguish clinically from telogen effluvium when hair loss is not severe. A biopsy can be used to differentiate between the two disorders. In addition, more pronounced hair thinning in the bitemporal region is more consistent with telogen effluvium than alopecia areata, and a positive hair pull test in alopecia areata may reveal both dystrophic anagen and telogen hairs in contrast to the isolated telogen hairs in telogen effluvium [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/15683.html" rel="external">"Telogen effluvium"</a>.)</p><p class="headingAnchor" id="H3449187788"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117218.html" rel="external">"Society guideline links: Alopecia"</a>.)</p><p class="headingAnchor" id="H16963455"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15436.html" rel="external">"Patient education: Hair loss (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/7631.html" rel="external">"Patient education: Alopecia areata (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Alopecia areata is a chronic, relapsing disorder characterized by nonscarring hair loss  (<a class="graphic graphic_picture graphicRef105455 graphicRef120370 graphicRef120368 graphicRef76247 graphicRef52784 graphicRef120371 graphicRef72738 graphicRef66057" href="/d/graphic/105455.html" rel="external">picture 1A-H</a>). The disorder can affect individuals of any age. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of alopecia areata is thought to involve autoimmune-mediated disruption of the normal hair cycle, leading to the inhibition of normal hair growth. A loss of the immune-privileged status of the hair follicle is considered a key pathogenic event. Genetic predisposition also contributes to the development of the disorder. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with alopecia areata most often present with smooth, circular, discrete areas of complete hair loss that develop over a period of a few weeks. Exclamation point hairs, short broken hairs for which the proximal end of the hair is narrower than the distal end, are a common finding  (<a class="graphic graphic_picture graphicRef120367" href="/d/graphic/120367.html" rel="external">picture 5A</a>). Patients may also have associated nail abnormalities. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course</strong> – The course of alopecia areata is unpredictable. Many patients with limited patchy hair loss experience regrowth within one year, but recurrence is common. A minority of patients may progress to total loss of scalp hair (alopecia totalis) or loss of all hair (alopecia universalis)  (<a class="graphic graphic_picture graphicRef50229 graphicRef120375" href="/d/graphic/50229.html" rel="external">picture 2A-B</a>). Poor prognostic factors for alopecia areata include young age of onset, severe disease, long duration of disease, ophiasis pattern, nail disease, and an atopic history. (See <a class="local">'Disease course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – Alopecia areata has been associated with a variety of autoimmune diseases and other disorders. (See <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of alopecia is often made via the patient history and physical examination. Biopsies can be performed in cases in which the diagnosis is uncertain. (See <a class="local">'Diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78:1.</a></li><li><a class="nounderline abstract_t">Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70:628.</a></li><li><a class="nounderline abstract_t">Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol 2014; 134:1141.</a></li><li><a class="nounderline abstract_t">Putterman E, Castelo-Soccio L. Seasonal patterns in alopecia areata, totalis, and universalis. J Am Acad Dermatol 2018; 79:974.</a></li><li><a class="nounderline abstract_t">Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol 2018; 179:1033.</a></li><li><a class="nounderline abstract_t">Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014; 20:1043.</a></li><li><a class="nounderline abstract_t">Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 2014; 134:2988.</a></li><li><a class="nounderline abstract_t">Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol 2017; 76:22.</a></li><li><a class="nounderline abstract_t">Gilhar A, Keren A, Shemer A, et al. Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata. J Invest Dermatol 2013; 133:844.</a></li><li><a class="nounderline abstract_t">Blaumeiser B, van der Goot I, Fimmers R, et al. Familial aggregation of alopecia areata. J Am Acad Dermatol 2006; 54:627.</a></li><li><a class="nounderline abstract_t">Jackow C, Puffer N, Hordinsky M, et al. Alopecia areata and cytomegalovirus infection in twins: genes versus environment? J Am Acad Dermatol 1998; 38:418.</a></li><li><a class="nounderline abstract_t">Rodriguez TA, Fernandes KE, Dresser KL, et al. Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors. J Am Acad Dermatol 2010; 62:525.</a></li><li><a class="nounderline abstract_t">Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466:113.</a></li><li><a class="nounderline abstract_t">Martinez-Mir A, Zlotogorski A, Gordon D, et al. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 2007; 80:316.</a></li><li><a class="nounderline abstract_t">Sundberg JP, Silva KA, Li R, et al. Adult-onset Alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Dermatol 2004; 123:294.</a></li><li><a class="nounderline abstract_t">Duvic M, Nelson A, de Andrade M. The genetics of alopecia areata. Clin Dermatol 2001; 19:135.</a></li><li><a class="nounderline abstract_t">McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002; 27:405.</a></li><li><a class="nounderline abstract_t">Barahmani N, de Andrade M, Slusser JP, et al. Human leukocyte antigen class II alleles are associated with risk of alopecia areata. J Invest Dermatol 2008; 128:240.</a></li><li><a class="nounderline abstract_t">Betz RC, Petukhova L, Ripke S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun 2015; 6:5966.</a></li><li><a class="nounderline abstract_t">Megiorni F, Pizzuti A, Mora B, et al. Genetic association of HLA-DQB1 and HLA-DRB1 polymorphisms with alopecia areata in the Italian population. Br J Dermatol 2011; 165:823.</a></li><li><a class="nounderline abstract_t">Willemsen R, Vanderlinden J, Roseeuw D, Haentjens P. Increased history of childhood and lifetime traumatic events among adults with alopecia areata. J Am Acad Dermatol 2009; 60:388.</a></li><li><a class="nounderline abstract_t">Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. Br J Dermatol 2014; 170:1299.</a></li><li><a class="nounderline abstract_t">Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366:1515.</a></li><li><a class="nounderline abstract_t">Muñoz MA, Camacho FM. Sisaipho: a new form of presentation of alopecia areata. Arch Dermatol 1996; 132:1255.</a></li><li><a class="nounderline abstract_t">Chartier MB, Hoss DM, Grant-Kels JM. Approach to the adult female patient with diffuse nonscarring alopecia. J Am Acad Dermatol 2002; 47:809.</a></li><li><a class="nounderline abstract_t">Lew BL, Shin MK, Sim WY. Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosis. J Am Acad Dermatol 2009; 60:85.</a></li><li><a class="nounderline abstract_t">Saceda-Corralo D, Grimalt R, Fernández-Crehuet P, et al. Beard alopecia areata: a multicentre review of 55 patients. J Eur Acad Dermatol Venereol 2017; 31:187.</a></li><li><a class="nounderline abstract_t">Kasumagic-Halilovic E, Prohic A. Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol 2009; 23:240.</a></li><li><a class="nounderline abstract_t">Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010; 62:177.</a></li><li><a class="nounderline abstract_t">Shapiro J, Madani S. Alopecia areata: diagnosis and management. Int J Dermatol 1999; 38 Suppl 1:19.</a></li><li><a class="nounderline abstract_t">MacDonald Hull SP, Wood ML, Hutchinson PE, et al. Guidelines for the management of alopecia areata. Br J Dermatol 2003; 149:692.</a></li><li><a class="nounderline abstract_t">Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol 2006; 55:438.</a></li><li><a class="nounderline abstract_t">De Waard-van der Spek FB, Oranje AP, De Raeymaecker DM, Peereboom-Wynia JD. Juvenile versus maturity-onset alopecia areata--a comparative retrospective clinical study. Clin Exp Dermatol 1989; 14:429.</a></li><li><a class="nounderline abstract_t">You HR, Kim SJ. Factors Associated with Severity of Alopecia Areata. Ann Dermatol 2017; 29:565.</a></li><li><a class="nounderline abstract_t">Mohan GC, Silverberg JI. Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis. JAMA Dermatol 2015; 151:522.</a></li><li><a class="nounderline abstract_t">Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006; 20:1055.</a></li><li><a class="nounderline abstract_t">Wang S, Ratnaparkhi R, Piliang M, Bergfeld WF. Role of family history in patchy alopecia areata. Dermatol Online J 2018; 24.</a></li><li><a class="nounderline abstract_t">Barahmani N, Schabath MB, Duvic M, National Alopecia Areata Registry. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 2009; 61:581.</a></li><li><a class="nounderline abstract_t">Wang SJ, Shohat T, Vadheim C, et al. Increased risk for type I (insulin-dependent) diabetes in relatives of patients with alopecia areata (AA). Am J Med Genet 1994; 51:234.</a></li><li><a class="nounderline abstract_t">Du Vivier A, Munro DD. Alopecia areata, autoimmunity, and Down's syndrome. Br Med J 1975; 1:191.</a></li><li><a class="nounderline abstract_t">Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol 2007; 24:317.</a></li><li><a class="nounderline abstract_t">Schepis C, Barone C, Siragusa M, et al. An updated survey on skin conditions in Down syndrome. Dermatology 2002; 205:234.</a></li><li><a class="nounderline abstract_t">Collins SM, Dominguez M, Ilmarinen T, et al. Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Br J Dermatol 2006; 154:1088.</a></li><li><a class="nounderline abstract_t">Vogel A, Strassburg CP, Obermayer-Straub P, et al. The genetic background of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy and its autoimmune disease components. J Mol Med (Berl) 2002; 80:201.</a></li><li><a class="nounderline abstract_t">Rencz F, Gulácsi L, Péntek M, et al. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol 2016; 175:561.</a></li><li><a class="nounderline abstract_t">Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. J Am Acad Dermatol 2016; 75:806.</a></li><li><a class="nounderline abstract_t">Ruiz-Doblado S, Carrizosa A, García-Hernández MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol 2003; 42:434.</a></li><li><a class="nounderline abstract_t">Ghanizadeh A. Comorbidity of psychiatric disorders in children and adolescents with alopecia areata in a child and adolescent psychiatry clinical sample. Int J Dermatol 2008; 47:1118.</a></li><li><a class="nounderline abstract_t">Koo JY, Shellow WV, Hallman CP, Edwards JE. Alopecia areata and increased prevalence of psychiatric disorders. Int J Dermatol 1994; 33:849.</a></li><li><a class="nounderline abstract_t">Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003; 139:1555.</a></li><li><a class="nounderline abstract_t">Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol 2006; 55:799.</a></li><li><a class="nounderline abstract_t">Inui S, Nakajima T, Nakagawa K, Itami S. Clinical significance of dermoscopy in alopecia areata: analysis of 300 cases. Int J Dermatol 2008; 47:688.</a></li><li><a class="nounderline abstract_t">Tosti A, Whiting D, Iorizzo M, et al. The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol 2008; 59:64.</a></li><li><a class="nounderline abstract_t">Miteva M, Tosti A. Hair and scalp dermatoscopy. J Am Acad Dermatol 2012; 67:1040.</a></li><li><a class="nounderline abstract_t">Abraham LS, Torres FN, Azulay-Abulafia L. Dermoscopic clues to distinguish trichotillomania from patchy alopecia areata. An Bras Dermatol 2010; 85:723.</a></li><li><a class="nounderline abstract_t">Lee S, Lee YB, Kim BJ, Lee WS. Screening of thyroid function and autoantibodies in patients with alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol 2019; 80:1410.</a></li><li><a class="nounderline abstract_t">Patel D, Li P, Bauer AJ, Castelo-Soccio L. Screening Guidelines for Thyroid Function in Children With Alopecia Areata. JAMA Dermatol 2017; 153:1307.</a></li><li><a class="nounderline abstract_t">Kaplan L, Castelo-Soccio L. When your patient's parent asks: "My child's alopecia areata is not getting better. Should he or she get tested for celiac disease?". Pediatr Dermatol 2018; 35:535.</a></li></ol></div><div id="topicVersionRevision">Topic 3320 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241771" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791384" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24202232" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30318138" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Seasonal patterns in alopecia areata, totalis, and universalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29791718" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Alopecia areata: a review of disease pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25129481" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24940651" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816293" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23096715" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16546583" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Familial aggregation of alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9520023" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Alopecia areata and cytomegalovirus infection in twins: genes versus environment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159328" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20596022" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17236136" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15245428" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adult-onset Alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11397591" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The genetics of alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12190641" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epidemiology and genetics of alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17637820" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Human leukocyte antigen class II alleles are associated with risk of alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25608926" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21692766" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Genetic association of HLA-DQB1 and HLA-DRB1 polymorphisms with alopecia areata in the Italian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026463" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased history of childhood and lifetime traumatic events among adults with alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24655364" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vitamin D deficiency in alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22512484" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8859050" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sisaipho: a new form of presentation of alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451364" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Approach to the adult female patient with diffuse nonscarring alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18992964" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27503140" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Beard alopecia areata: a multicentre review of 55 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18540984" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nail changes in alopecia areata: frequency and clinical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20115945" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369536" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Alopecia areata: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616359" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Guidelines for the management of alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908349" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Alopecia areata: a long term follow-up study of 191 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2605805" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Juvenile versus maturity-onset alopecia areata--a comparative retrospective clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28966512" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Factors Associated with Severity of Alopecia Areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25471826" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16987257" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30677822" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Role of family history in patchy alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608295" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : History of atopy or autoimmunity increases risk of alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8074151" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Increased risk for type I (insulin-dependent) diabetes in relatives of patients with alopecia areata (AA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/122906" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Alopecia areata, autoimmunity, and Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17542890" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mucocutaneous findings in 100 children with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399669" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An updated survey on skin conditions in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704638" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11976729" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The genetic background of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy and its autoimmune disease components.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26914830" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Alopecia areata and health-related quality of life: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27436156" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12786868" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Alopecia areata: psychiatric comorbidity and adjustment to illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18986440" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comorbidity of psychiatric disorders in children and adolescents with alopecia areata in a child and adolescent psychiatry clinical sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7883407" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Alopecia areata and increased prevalence of psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14676070" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Histopathologic features of alopecia areata: a new look.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17052485" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Videodermoscopy in the evaluation of hair and scalp disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18613874" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical significance of dermoscopy in alopecia areata: analysis of 300 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440667" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The role of scalp dermoscopy in the diagnosis of alopecia areata incognita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22405573" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hair and scalp dermatoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21152803" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dermoscopic clues to distinguish trichotillomania from patchy alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30447313" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Screening of thyroid function and autoantibodies in patients with alopecia areata: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973128" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Screening Guidelines for Thyroid Function in Children With Alopecia Areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29797748" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : When your patient's parent asks: "My child's alopecia areata is not getting better. Should he or she get tested for celiac disease?"</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
